Go to the profile of Genome and Company

Genome and Company

 

About Genome and Company

Genome & Company is a research base biotech with development programs in microbiome based therapeutics, dietary supplements, cosmeceuticals, and novel target innovator drugs in immuno-oncology. We have been studying microbes and probiotics which can be applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies with the vision of becoming the flagship company of the human microbiome industry. We seek to identify what causes diseases, integrating the functional mechanism using a simulator of the human colon microbial ecosystem and multi-omics profiling through next generation sequencing. Currently, Genome & Company’s technology and capabilities are evidenced by partnerships with Major hospitals, Schools, Research Institutes and Governments; and it’s our privilege to be able to focus exclusively on research & development thanks to upwards of $50M trough series C financing, and our market capitalization being valued at approximately $400M in a Korean stock exchange.

Therapeutic Areas

Oncology

Technologies

Biologics

Company Type

Biotechnology – Therapeutics

State of Ownership

Public

Sponsorship Group

Leader Partner Networker

Influencer Of

Topics

Editions participated in:

September 2019